Healthcare Industry News: Caris Life Sciences
News Release - January 12, 2011
Caris Life Sciences Launches Caris Target Now(TM) Ovarian ProfileNovel Profile to Provide Physicians With Personalized Therapeutic Information for Women Facing Often Fatal Ovarian Cancer
IRVING, Texas, Jan. 12, 2011 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced the launch of a new Caris Target Now molecular profile for ovarian cancer patients. This expansion of the Caris Target Now offering provides individualized molecular information to treating physicians, relevant to the selection of therapies to treat this highly-lethal cancer. Ovarian cancer affects more than 20,000 women annually with some of the highest five-year mortality rates found in cancer.
Caris Target Now molecular profiling examines the unique genetic and molecular make-up of each patient's tumor so that treatment options may be matched to each patient individually. With 300% growth in utilization in 2010, medical oncologists are recognizing the utility and value of this novel approach in providing improved care to patients. Since the introduction of the service, more than 15,000 patients have received therapeutic drug guidance in their cancer treatment decisions using Caris Target Now. Physician adoption is rapidly accelerating, as Caris recently reached the threshold of providing Caris Target Now services to more than 1,000 patients per month. This new introduction for ovarian cancer is most relevant for physicians treating women who have progressed on platinum-based therapy and/or who need guidance for third line treatment options. Caris Target Now for ovarian cancer offers the opportunity for these women to benefit from personalized and targeted therapy guidance based upon molecular profiling.
"Ovarian cancer is a highly-lethal cancer that presents distinct diagnostic and therapeutic challenges, often presenting no major symptoms until the cancer has metastasized," said Dr. Les Paul, Caris' Senior Vice President for Medical Affairs. "Choosing the optimal therapeutic intervention at the earliest possible stage is critical to extending progression free survival in ovarian cancer patients. With the introduction of the Caris Target Now ovarian profile, we are able to support physicians with as much information as possible, including the latest relevant clinical literature citations to aid them in making the best therapeutic decision possible for each patient."
About Caris Life Sciences
Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome(TM) platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, and operates laboratories at the headquarters, as well as in the Phoenix and Boston metro areas.
Source: Caris Life Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsCaris Life Sciences Appoints Steven D. Averbuch, M.D., to Its Scientific Advisory Board
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
Caris Life Sciences Receives FDA Breakthrough Device Designation for MI Transcriptome(TM) Companion Diagnostic Test